DIPHENHYDRAMINE HYDROCHLORIDE
Sponsors
Celgene Corp., Moderna Inc., Bioinvent International AB, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale, Rocket Pharmaceuticals Inc.
Conditions
Advanced solid tumorsAutonomic FailureChildhood Idiopathic Nephrotic SyndromeDanon DiseaseExerciseHIV InfectionsHealthyHigh risk smoldering multiple myeloma
Phase 1
Treatment of Orthostatic Hypotension in Autonomic Failure
CompletedNCT00223691
Start: 2002-03-31End: 2017-01-31Updated: 2017-01-18
Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride
CompletedNCT00662337
Start: 2006-10-31End: 2006-11-30Updated: 2011-09-08
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705.
RecruitingCTIS2022-501997-20-00
Start: 2023-12-01Target: 26Updated: 2025-12-12
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
CompletedCTIS2022-503066-74-00
Start: 2023-12-04End: 2025-12-17Target: 186Updated: 2025-10-07
Phase 2
Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously Administered Adeno-Associated Virus Serotype 9 (rAAV9) Vector Containing the Human LAMP2 Isoform B Transgene (RP-A501; AAV9.LAMP2B) in Male Patients with Danon Disease
SuspendedCTIS2023-506480-34-00
Start: 2024-06-18Target: 4Updated: 2025-02-13
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
RecruitingCTIS2023-505775-70-00
Start: 2024-04-08Target: 105Updated: 2026-01-13
C1131003 - AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA
Active, not recruitingCTIS2023-509338-21-00
Start: 2025-05-28Target: 42Updated: 2025-12-15
Phase 3
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
Active, not recruitingNCT04963296
Start: 2021-10-26End: 2028-03-14Updated: 2026-01-07
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
Active, not recruitingNCT05627557
Start: 2023-03-29End: 2026-09-04Updated: 2025-12-15
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Active, not recruitingCTIS2022-501346-30-00
Start: 2023-09-25Target: 332Updated: 2025-12-09
Phase 4
Unknown Phase
Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection
TerminatedNCT00000875
End: 2003-04-30Target: 16Updated: 2016-12-14
Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers
CompletedNCT01204255
Start: 2010-11-15End: 2011-05-17Updated: 2017-11-17
Histamines and Central Hemodynamics
RecruitingNCT07285031
Start: 2025-12-31End: 2026-08-31Target: 20Updated: 2025-12-23